Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Decreases By 57.0%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 27,500 shares, a decrease of 57.0% from the February 28th total of 63,900 shares. Based on an average daily trading volume, of 284,400 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.

Oncotelic Therapeutics Stock Down 1.7 %

Shares of OTCMKTS OTLC opened at $0.07 on Friday. The stock has a market capitalization of $27.95 million, a P/E ratio of -6.88 and a beta of -0.25. Oncotelic Therapeutics has a one year low of $0.02 and a one year high of $0.07. The firm’s 50 day simple moving average is $0.04 and its two-hundred day simple moving average is $0.03. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.01 and a quick ratio of 0.01.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.